Ga naar hoofdinhoud

NVRA

NASDAQ

Novara Biotech

Healthcare · Biotechnology

Updated UTC

US$ 410,77

+5,46+1,35%

After hoursUS$ 412,82+0,50%

350,00400,0005/2106/2608/0309/0710/1311/18410,77

130 candlesRange +20,09%

Key statistics

Open
US$ 405,06
High
US$ 411,55
Low
US$ 402,66
Previous close
US$ 405,31
Volume
3,81 mln.
Average volume
3,14 mln.
Marktkapitalisatie
393,65 mld.
P/E ratio
37,55
EPS
US$ 10,94
Dividend yield
—
52-week high
US$ 412,94
52-week low
US$ 295,67

Financial statements

Units: USD · Annual
ItemFY2022FY2023FY2024FY2025FY2026
Revenue31,67 mld.37,26 mld.41,96 mld.48,31 mld.53,67 mld.
Gross profit18,76 mld.21,53 mld.23,9 mld.26,46 mld.32,34 mld.
Operating income6,26 mld.7,62 mld.7,85 mld.9,58 mld.11,72 mld.
Net income4,88 mld.5,63 mld.6,17 mld.5,78 mld.7,65 mld.

About the company

Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.

Related news

Demo
  • Novara Biotech reports quarterly revenue above the internal plan

    Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.

    Sector Desk

  • Novara Biotech expands manufacturing capacity in Cambridge

    The company approved a multi-year capital program intended to shorten lead times for its largest customers.

    Sector Desk

  • Analyst note trims Novara Biotech price target on valuation

    A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.

    Sector Desk

  • Novara Biotech appoints new chief financial officer

    The board named an internal candidate with prior treasury and investor-relations experience to the role.

    Sector Desk

  • Novara Biotech announces share repurchase authorization

    The authorization covers a modest slice of the float and will be funded from operating cash flow.

    Terminal Brief